Pfenex

^{Priced, NYSE American: PFNX}

Developing a biosimilar version of Roche's Lucentis treatment for wet AMD.

Industry: Health Care

First Day Return: -11.7%

PFNX

Developing a biosimilar version of Roche's Lucentis treatment for wet AMD.

IPO News for Pfenex

Year's fourth eye-focused biotech EyeGate Pharmaceuticals sets terms for $25 million IPO 09/14/14
US IPO Pricing Recap: The crazy chicken flies while 8 IPOs trade down or flat 07/25/14
Thursday saw four IPOs raise under $100 million; two broke issue 07/24/14

IPO Data
IPO Date	07/23/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$50
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.pfenex.com
Headquarters	San Diego, CA, United States
Founded	2009
Employees at IPO	25

IPO News for Pfenex

Pfenex (PFNX) Performance